Product Description
NUC-1031 (Acelarin), a phosphoramidate transformation of gemcitabine, was the first anti-cancer ProTide to enter the clinic. We find it displays important in vitro cytotoxicity differences to gemcitabine, and a genome-wide CRISPR/Cas9 genetic screening approach identified only the pyrimidine metabolism pathway as modifying cancer cell sensitivity to NUC-1031. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31113993/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: Fast Track - Biliary Tract Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Nucana
Company Location: Europe
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acinar Cell Carcinoma|Pancreatic Cancer|Biliary Tract Cancer|Adenocarcinoma|Gallbladder Cancer
Phase 2: Ovarian Cancer|Fallopian Tube Cancer
Phase 1: Ovarian Cancer|Cholangiocarcinoma|Gallbladder Cancer|Biliary Tract Cancer|Liver Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02351765 |
ABC-08 | P1 |
Completed |
Gallbladder Cancer|Cholangiocarcinoma|Biliary Tract Cancer |
2019-03-01 |
2019-08-10 |
Primary Endpoints|Treatments|Trial Status |
|
NCT02303912 |
ProGem2 | P1 |
Completed |
Ovarian Cancer |
2017-01-23 |
2019-04-11 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT01621854 |
ProGem1 | P1 |
Completed |
Liver Cancer |
2015-06-01 |
2019-03-19 |
Treatments |
|
2016-003287-39 |
2016-003287-39 | P2 |
Terminated |
Fallopian Tube Cancer|Ovarian Cancer |
2019-12-31 |
2025-07-04 |
Treatments |
|
NCT03146663 |
PRO-105 | P2 |
Terminated |
Ovarian Cancer |
2019-12-31 |
2021-02-22 |
Patient Enrollment|Primary Endpoints|Treatments |
|
2019-001025-28 |
2019-001025-28 | P3 |
Unknown status |
Biliary Tract Cancer|Adenocarcinoma|Gallbladder Cancer |
2023-06-06 |
2022-03-13 |
Treatments |
|
NCT04163900 |
NuTide:121 | P3 |
Terminated |
Biliary Tract Cancer |
2022-03-02 |
2022-04-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03610100 |
ACELARATE | P3 |
Suspended |
Acinar Cell Carcinoma|Pancreatic Cancer |
2020-09-01 |
2019-10-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2014-004653-14 |
ACELARATE | P3 |
Unknown status |
Pancreatic Cancer |
2018-02-07 |
2025-06-29 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/02/2022 |
News Article |
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study |
|
02/28/2022 |
News Article |
NuCana to Participate in Two Upcoming Investor Conferences |
|
11/10/2021 |
News Article |
NuCana to Present at the Jefferies 2021 London Healthcare Conference |
|
09/29/2021 |
News Article |
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer |